首页> 外文期刊>American Journal of Cancer Research >Wnt2 promotes non-small cell lung cancer progression by activating WNT/?2-catenin pathway
【24h】

Wnt2 promotes non-small cell lung cancer progression by activating WNT/?2-catenin pathway

机译:Wnt2通过激活WNT /β2-catenin途径促进非小细胞肺癌的进展

获取原文
           

摘要

Background: Wnt2 is overexpressed and able to promote tumorigenesis in many types of cancer. However, its expression and role in lung cancer has not been well clarified yet. In this study, we aims to investigate the expression pattern, clinical significance and the underlying molecular mechanism of Wnt2 in non-small lung cancer (NSCLC). Methods: Immunohistochemical staining and ELISA assays were applied to detect Wnt2 level in tumor tissue and serum. EDU incorporation assays and colony formation assays were used to evaluate the growth-promoting effect of Wnt2 in vitro. Then we performed western blot and immunofluorescence assays to detect the activation of WNT signaling pathway. Finally mice engrafted with NSCLC tumor cells were used to assess the role of Wnt2 in vivo. Results: Immunohistochemical staining consisting of 264 NSCLC tumor tissues showed that a high level of Wnt2 was associated with a poor overall survival (OS) and relapse-free survival (RFS) of NSCLC patients (P = 0.002 and 0.0005, respectively). Multivariate analysis presented that Wnt2 level in tumor tissue was an independent prognostic factor (P = 0.049 for OS and P = 0.002 for RFS, respectively). Furthermore, ELISA assays for 181 individuals (116 NSCLC and 65 controls) revealed that serum Wnt2 levels in adenocarcinoma was significantly higher than that in healthy volunteers (P < 0.0001). In vitro H460 cell line stably overexpressing Wnt2 showed enhanced growth activity than the control cells whereas knockdown of Wnt2 by siRNA in H1299 cells resulted in decreased growth activity. Additionally, Wnt2 level in tumor tissues was significantly associated with Ki-67 level (rs: 0.316; P < 0.0001). Immunofluorescence and Western blot assays detected the translocation of β-catenin from cytoplasm into nucleus, which indicated that Wnt2 probably promotes proliferation by activating WNT/β-catenin pathway. In vivo H460 cells expressing exogenous Wnt2 showed increased growth-promoting effect in Balb/c nude mice than control cells. Conclusions: The present study for the first time suggested that Wnt2 was both a prognostic and a diagnostic biomarker for NSCLC. Tumor-derived Wnt2 can promote growth activity of NSCLC cells through activating WNT/β-catenin signaling pathway.
机译:背景:Wnt2过表达并且能够促进许多类型癌症中的肿瘤发生。然而,其在肺癌中的表达和作用尚未得到很好的阐明。在这项研究中,我们旨在调查Wnt2在非小细胞肺癌(NSCLC)中的表达模式,临床意义和潜在的分子机制。方法:采用免疫组织化学染色和ELISA法检测肿瘤组织和血清中的Wnt2水平。 EDU掺入测定法和菌落形成测定法用于评价Wnt2在体外的促生长作用。然后,我们进行了免疫印迹和免疫荧光分析,以检测WNT信号通路的激活。最后,将移植有NSCLC肿瘤细胞的小鼠用于评估体内Wnt2的作用。结果:由264个NSCLC肿瘤组织组成的免疫组织化学染色显示,高水平的Wnt2与NSCLC患者的较差的总生存期(OS)和无复发生存期(RFS)相关(分别为P = 0.002和0.0005)。多变量分析表明,肿瘤组织中的Wnt2水平是一个独立的预后因素(OS的P = 0.049和RFS的P = 0.002)。此外,针对181位个体(116位NSCLC和65位对照)的ELISA分析显示,腺癌中的血清Wnt2水平显着高于健康志愿者(P <0.0001)。稳定表达Wnt2的体外H460细胞系比对照细胞显示出增强的生长活性,而siRNA在H1299细胞中敲低Wnt2导致生长活性降低。另外,肿瘤组织中的Wnt2水平与Ki-67水平显着相关(rs:0.316; P <0.0001)。免疫荧光和Western印迹法检测到β-catenin从细胞质向核内移位,这表明Wnt2可能通过激活WNT /β-catenin途径促进增殖。在体内,表达外源性Wnt2的H460细胞在Balb / c裸鼠中的生长促进作用高于对照细胞。结论:本研究首次表明,Wnt2是NSCLC的预后和诊断生物标志物。肿瘤来源的Wnt2可以通过激活WNT /β-catenin信号通路来促进NSCLC细胞的生长活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号